Corporate Information And Statement Of Ifrs Compliance [Abstract]

ERYTECH Pharma S.A. - Filing #2810992

Concept	As at 2023-12-31	2023-01-01 to 2023-12-31	As at 2022-12-31	As at 2021-12-31
Corporate information and statement of IFRS compliance [abstract]
Name of reporting entity or other means of identification	—	PHAXIAM Therapeutics	—	—
Legal form of entity	—	société anonyme	—	—
Country of incorporation	—	France	—	—
Address of entity's registered office	—	60 Avenue	—	—
Description of nature of entity's operations and principal activities	—		—	—
Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [text block]	—	—	—	—
Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [abstract]
Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [line items]
Current inventories	— EUR	—	— EUR	— EUR
Current trade receivables	103,000 EUR	—	76,000 EUR	12,000 EUR
Disclosure of material accounting policy information [text block]	—		—	—
Disclosure of objectives, policies and processes for managing capital [text block]	—		—	—